Literature DB >> 18682769

Dr. North's rebuttal.

Scott North1.   

Abstract

Year:  2008        PMID： 18682769      PMCID： PMC2494890     

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

Review 1.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.

Authors:  Eric Winquist; Tricia S Kirchner; Roanne Segal; Joseph Chin; Himu Lukka
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

2.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

3.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

4.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Authors:  P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

5.  Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.

Authors:  M Stöckle; W Meyenburg; S Wellek; G E Voges; M Rossmann; U Gertenbach; J W Thüroff; C Huber; R Hohenfellner
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

6.  Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial.

Authors:  U E Studer; M Bacchi; C Biedermann; P Jaeger; R Kraft; L Mazzucchelli; R Markwalder; E Senn; R W Sonntag
Journal:  J Urol       Date:  1994-07       Impact factor: 7.450

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

Authors:  F Freiha; J Reese; F M Torti
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

9.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.

Authors:  D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

Review 10.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.